Related Experiment Video

Updated: Jul 13, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Pharmacologic therapy of chronic heart failure

Eman Hamad1, Paul J Mather, Siva Srinivasan

  • 1Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|August 19, 2007
PubMed

Insights

Understanding heart failure progression reveals that neurohormonal system activation, while protective acutely, causes chronic damage. Targeting this system is key, but other treatments are vital for advanced heart failure.

Area of Science:

  • Cardiology
  • Pathophysiology
  • Pharmacology

Background:

  • Investigated pathophysiologic changes in systolic and diastolic dysfunction over 20 years.
  • Identified chronic activation of protective biologic pathways contributing to progressive heart damage.
  • Highlighted the significant impact of neurohormonal system activation on disease progression.

Purpose of the Study:

  • To explore the role of the neurohormonal system in heart failure progression.
  • To identify key targets for pharmacologic therapy in systolic dysfunction.
  • To discuss limitations of neurohormonal manipulation in end-stage heart failure.

Main Methods:

  • Review of pathophysiologic changes in heart failure.
  • Analysis of neurohormonal system activation pathways.
  • Evaluation of pharmacologic therapies for heart failure.

Main Results:

  • Chronic activation of neurohormonal pathways leads to deleterious effects.
  • The renin-angiotensin-aldosterone system and sympathetic nervous system are key targets.
  • Neurohormonal manipulation shows limited efficacy in end-stage heart failure.

Conclusions:

  • Pharmacologic therapy targeting the neurohormonal system is crucial for systolic dysfunction.
  • Alternative strategies are necessary for end-stage heart failure.
  • Inotropic agents and diuretics are important for managing pump function and fluid balance.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...